Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Summary Daratumumab refractoriness significantly worsens outcomes after CAR T-cell therapy in patients with relapsed/refractory multiple myeloma. Studies show Read More
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series Summary This case series highlights a newly recognized side effect of talquetamab, a GPRC5D-targeting bispecific antibody used to treat multiple Read More
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma Summary Real-world data on idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) CAR-T therapy for multiple Read More
Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma Summary Immune effector cell-associated enterocolitis (IEC-associated enterocolitis) is an emerging complication following CAR-T therapy for multiple myeloma. Characterized by diarrhea, abdominal pain, and potential intestinal inflammation, Read More
1 Million+ Views and Counting..!
Now, it has been 6 years since it was launched in late July 2018 and is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
